comparemela.com

Latest Breaking News On - Argininosuccinate synthetase - Page 1 : comparemela.com

Frontiers | Systems Immunology Analysis Reveals the Contribution of Pulmonary and Extrapulmonary Tissues to the Immunopathogenesis of Severe COVID-19 Patients

2Luebeck Institute of Experimental Dermatology, University of Luebeck, Luebeck, Germany 3General Surgery Department, Tawam Hospital, SEHA, Al Ain, United Arab Emirates 4Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates 5Department of Genetics and Molecular Biology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates 6Department of Respiratory Medicine, Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates 7Meakins-Christie Laboratories, McGill University, Montreal, QC, Canada 8Division of Surgery and Interventional Science, University College London, London, United Kingdom As one of the current global health conundrums, COVID-19 pandemic caused a dramatic increase of cases exceeding 79 million and 1.7 million deaths worldwide. Severe presentation of COVID-19 is characterized by cytokine storm and chronic inflammation resulting in multi-organ dysfunction. Currently, it is unclear whet

Global Urea Cycle Disorders Treatment Market to Surpass US$ 1,510 2 Million by 2027, Says Coherent Market Insights (CMI)

: The rising prevalence of urea cycle disorders is expected to increase the demand for treatment options for urea cycle disorders (UCD), which is expected to drive the growth of global urea cycle disorders treatment market during the forecast period. According to the Urea Cycle Disorders Consortium (UCDC), a part of the Rare Diseases Clinical Research Network (RDCRN), combined prevalence of urea cycle disorders is around 1 in 30,000 people in the U.S in 2017 Among regions, North America is expected to hold dominant position in the global urea cycle disorders treatment market during the forecast period, owing to key companies focusing on product launches for the treatment of Urea cycle disorders. For instance, in January 2021, Recordati Rare Diseases Inc. received the U.S. Food and Drug Administration (FDA) approval for CARBAGLU for the treatment of acute hyperammonemia.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.